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Abstract 
Background:  
Since Glenner and Wong’s amyloid hypothesis, in which accumulations of amyloid 
proteins cause Alzheimer’s Disease (AD), was first proposed in 1984, the questions about why 
amyloid proteins accumulate in the first place remain. One hypothesis, known as the 
infection/infectious hypothesis, postulates that bacterial, viral, or fungal infections in the brain 
cause chronic inflammation which results in accumulation of amyloid proteins. Although the 
association between HSV-1 and AD has been extensively studied, evidence of association 
between AD and other pathogens remains inconclusive. The purpose of this systematic review is 
to summarize the literature examining the association between influenza virus/vaccine and AD.  
Methods: 
The authors searched four databases (PUBMED, PsycINFO, EMBASE, and EBSCO) to 
find articles that examined association between influenza virus/vaccine and AD. Two reviewers 
examined each article for its adherence to pre-specified inclusion and exclusion criteria, and the 
third reviewer settled any ties. The quality of included studies was assessed using guidelines 
developed by The Duke Evidence-based Practice Center, based on guidance from the Agency for 
Healthcare Research and Quality (AHRQ). 
Results: 
 Three studies met full eligibility criteria; none showed a statistically significant 
association between influenza infection/vaccine and the risk of AD. Studies assessed 
heterogeneous exposures. One (N=3865) showed a non-statistically significant reduction in AD 
risk in subjects who received influenza vaccine. The second (N=19463) did not show any 
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association between previous influenza infection and the risk of AD. The third found no 
association between in utero influenza exposure and the risk of AD.  
Conclusions: 
 The three included studies did not find any association between influenza 
infection/vaccine and the risk of AD. However, studies were heterogeneous in terms of 
population, exposure and outcome measurements, which limits the ability to make a conclusion.  
There remains a lack of large robust studies that study this association. Therefore, future studies 
that examine this relationship should include prospective design with large cohorts and use 
exposure and outcome measurements that minimize bias.  
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Introduction 
 Although previous studies have identified a number of potential genetic, environmental, 
and medical risk factors for Alzheimer’s disease (AD), the cause of AD remains unknown. The 
amyloid hypothesis, first proposed in 1984 by Glenner and Wong, postulates that the 
accumulation of amyloid-b proteins is crucial in the pathogenesis of the disease (Glenner, 2012). 
More than 30 years later, it is now one of the commonly proposed theories of AD pathogenesis. 
However, questions about how amyloid-b proteins accumulate in the first place remain. One 
promising theory is the infectious hypothesis. First introduced in the 1980’s with studies 
indicating a link between herpes simplex virus (HSV) and AD ( a M. Deatly, Spivack, Lavi, 
O’Boyle, & Fraser, 1988; A. M. Deatly, Haase, Fewster, Lewis, & Ball, 1990; Mann, Yates, 
Davis, & Hawkes, 1981; McGeer, Itagaki, Tago, & McGeer, 1987; Middleton, Petric, Kozak, 
Rewcastle, & Crapper McLachlan, 1980), this theory postulates that chronic inflammation of the 
brain caused by viral, bacterial, or fungal infections lead to plaque formation and subsequent 
development of AD.  
Numerous studies (Agostini et al., 2016; Carbone et al., 2014; Kobayashi et al., 2013; 
Tsolaki, Kountouras, Topouzis, & Tsolaki, 2015; Westman et al., 2017) have since examined the 
relationship between various infectious agents and the risk of AD. Out of the probable pathogens 
of AD, HSV-1 has perhaps been most extensively studied (Agostini et al., 2016; X.-L. Bu et al., 
2015; Kobayashi et al., 2013; Lövheim, Gilthorpe, Johansson, et al., 2015; Lövheim, Gilthorpe, 
Adolfsson, Nilsson, & Elgh, 2015; Ukraintseva et al., 2017). These studies have often compared 
antibodies or viral burdens of healthy controls and persons with AD. For example, Bu et al. 
(2015) showed that, compared to age and gender-matched cognitively healthy controls, AD 
patients had a higher infectious burden (measured by serum antibodies) of CMV, HSV-1, B. 
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burgdorferi, C. pneumoniae, and H. Pylori (X. L. Bu et al., 2015). Kobayashi et al. (2013) found 
that patients with mild cognitive impairment had higher anti-HSV-IgG titers than patients with 
AD, suggesting that prevention of reactivation of HSV by IgG antibodies is associated with 
decreased risk of AD (Kobayashi et al., 2013). 2017 study by Westman et al. measured HSV-1 
IgG levels in 50 AD participants and 52 healthy controls and found that there was no antibody 
level difference between the two groups (Westman et al., 2017). Comparing biomarkers of 
infection between AD subjects and healthy controls employed by these studies is the most direct 
way of drawing conclusions about the relationship between pathogens and AD. However, 
because of the resources needed to recruit eligible participants and to collect/process samples, 
these studies are limited by the small number of participants. For example, studies by Bu et al. 
and Kobayashi et al. 263 and 113 participants, respectively.  
On the other hand, several studies have examined the relationship between infection and 
AD using larger samples of participants but with less direct measurements of infection. Tyas et 
al. (2001) examined 694 subjects in Manitoba, Canada for multiple risk factors of AD in the 
Manitoba Study of Health and Aging (MSHA) using risk factor questionnaire as measures. They 
found that receiving any of the vaccines measured in the study (influenza, tetanus, diphtheria, 
polio) decreased the risk of AD (Tyas, Manfreda, Strain, & Montgomery, 2001). A study by Liu 
et al. (2016) used the National Health Insurance Research Database of Taiwan to examine 11,943 
subjects and concluded that influenza vaccination was found to be an independent protective 
factor against the development of dementia in patients with chronic kidney disease (CKD) (Liu 
et al., 2016). Finally, Ukraintseva et al. used ICD-9 codes in elderly Medicare subjects 
(approximately 30,000 participants) and found an association between being diagnosed with 
herpes virus and risk of developing AD (Ukraintseva et al., 2017). Because these are cohort 
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studies with larger number of subjects, they are able to provide more generalizable conclusions 
to the population at large. However, the use of indirect measures of infection (insurance claims, 
medical records, etc.) in these studies introduces concern for confounding factors.  
In addition, there is inherent difficulty in studying the association between pathogens and 
risk of AD using conventional case-control and cohort studies due to the nature of the disease. 
First, AD develops over decades which makes it difficult to determine what factors have caused 
the pathogenesis of the disease in the first place. Second, it is likely that individuals susceptible 
to infection with one pathogen are more susceptible to individuals with other pathogens. This 
means that even if individuals with HSV-1 (or any other specific pathogens for that matter) were 
to be found with higher risk of developing AD, there is a serious risk of confounding by other 
pathogens. Therefore, it may be useful to establish the risk of AD with more common pathogens 
first. For this reason, the authors sought to examine the association between influenza virus and 
the risk of developing AD.  
Influenza virus and vaccine occupy an important space in the public health policy sphere. 
Current guidelines from the Centers for Disease Control and Prevention recommend that 
everyone above 6-months of age receive an influenza vaccination annually (CDC, 2017b). 
Elderly adults above the age of 65 are especially at high risk for serious complications of 
influenza such as pneumonia and exacerbation of underlying pulmonary and cardiac diseases 
(Rothberg, Haessler, & Brown, 2008). Despite the importance of an annual influenza 
vaccination, National Immunization Survey-Flu (NIS-Flu) and Behavioral Risk Factor 
Surveillance System (BRFSS) found the vaccination rate among adults in the U.S. in 2016 – 
2017 influenza season to be only 43.3 percent (CDC, 2017a). There are several possible factors 
contributing to the low rate of influenza vaccination in the U.S. First is the perception of the 
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ineffectiveness of the influenza vaccine. CDC reports the influenza vaccine effectiveness in the 
recent years varies from 10 percent in 2004 – 2005 season to 60 percent in 2010 – 2011 season 
(CDC, 2018). This is much lower than vaccines such as the varicella vaccine, which had reported 
efficacy of 78.9 percent from 1997 – 2002 (Goldman & King, 2013). Second, the growth of anti-
vaccination movement in recent years has led the public to doubt the effectiveness and safety of 
vaccines (Kata, 2010). Consequently, in addition to searching the scientific literature for the 
strength and validity of the association between one the most common pathogens (influenza) and 
the risk of developing AD, it has become important to study the positive effects of the influenza 
vaccination from the public health standpoint.  
 
Methods 
Data Sources and Searches 
To identify relevant articles for this systematic review, we searched the following 
publication databases: PUBMED, PsycINFO, EMBASE, and EBSCO. The exact advanced 
search terms used for these databases are included in Appendix A (Table 2). Generally, we 
searched for articles published from 1984 to May 2018 with keywords containing both 
Alzheimer’s disease and influenza vaccine (and variations of those keywords). We restricted the 
search to articles written in English and to research involving humans only. We then excluded 
articles about vaccines for Alzheimer’s Disease by searching for keywords: Alzheimer’s Disease 
vaccines, vaccine for Alzheimer’s, and tau vaccine.  
 
Study Selection 
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Using Covidence.org, two authors independently screened all titles and abstracts 
identified in the searches described above. Any study that explicitly did not meet any of the 
exclusion criteria (Table 1) were excluded. Full-text articles of abstracts marked as potentially 
relevant were reviewed again using the same eligibility criteria. Exclusion and inclusion criteria 
are shown in Table 1. Figure 1 shows the number of articles reviewed at each stage of 
determining eligibility. Any conflicts between the two reviewing authors were resolved by the 
third reviewer.  
 
Data Extraction and Quality Assessment 
For studies that met full inclusion criteria, standardized data extraction and quality 
assessment were performed based on guidelines developed by The Duke Evidence-based 
Practice Center, based on guidance from Agency for Healthcare Research and Quality (AHRQ). 
Information abstracted from each study included the following: study design, number of 
participants, follow-up duration, inclusion/exclusion criteria, exposures, measurements, 
important baseline differences, and outcomes. Quality assessment comprised of 11 questions that 
assessed potential bias related to the following: selection bias, baseline characteristics, adequacy 
of sample size, measurement bias (of exposure and outcome), adequacy of the follow-up period, 
confounding, and appropriateness of analytic methods. The full list of data extraction and quality 
assessment questions are shown in Appendix C.  
 
Results 
Figure 1 summarizes the results of the literature. Of the 235 articles found initially in 
database searches, 22 articles were removed as duplicates. The remainder (199 studies) were 
excluded based on one or more criteria outlined in the exclusion criteria above. Of the 14 studies 
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that underwent full-text review, 3 were ultimately included (Figure 1). Description of study 
cohorts, methods, and results are presented below.  
 
Evidence Summary 
 The three included studies were heterogeneous in terms of study design, setting, and 
exposure/outcome measures. Two studies were cohorts (prospective and retrospective) (Cocoros, 
Horváth-puhó, Henderson, & Sørensen, 2018; R Verreault, Laurin, Lindsay, & De Serres, 2001), 
and one was a case-control study (Imfeld, Toovey, Jick, & Meier, 2016a). Studies enrolled 
participants from diverse country settings, including the U.K., Canada, and Denmark. In terms of 
exposures, studies focused on different measures; two measured previous influenza virus 
exposure (Imfeld et al., 2016a; R Verreault et al., 2001), and one measured past exposure to 
influenza vaccine (Cocoros et al., 2018). Outcome measures were consistent; all three studies 
measured AD as the main outcome. Control groups for studies differed; one study used matched 
controls without AD (Imfeld et al., 2016a), one used participants who did not develop AD during 
the study period as controls (R Verreault et al., 2001), and one used control group who were not 
exposed to influenza in utero (Cocoros et al., 2018). Overall, no study found a statistically 
significant association between influenza infection or influenza vaccine exposure and risk of AD.  
 
Detailed Summary of Individual Studies 
1. Past exposure to vaccines and subsequent risk of Alzheimer’s disease (René Verreault, 
Laurin, Lindsay, & De Serres, 2001) 
 CSHA was a cohort study of the epidemiology of cognitive impairment among 
community-dwelling older Canadians.  From 1991 to 2001, authors collected information at 5-
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year intervals on over 10,000 Canadians 65 or older from 36 communities to gather generalizable 
data on dementia (CSHA, 2002). In 1991, 9,008 randomly selected CSHA participants 
completed baseline cognitive screening with the Modified Mini-Mental State examination (René 
Verreault et al., 2001). Of these participants, the 7740 determined to be cognitively unimpaired 
at baseline, completed a self-administered risk factor questionnaire which included questions 
asking whether the participants had ever received vaccinations for diphtheria, tetanus, 
poliomyelitis, and influenza. These individuals were contacted 5 years later (1996 – 1997) to 
determine new cases of AD. Authors analyzed data on participants who completed the 5-year 
follow-up who were cognitively unimpaired (N=3682) and who were newly diagnosed with AD 
(N=183). Baseline characteristics of the two groups are described in Appendix C.  
 Authors adjusted found no significant association between previous vaccine status and 
risk of developing AD after adjusting for relevant confounders (age, sex, education, smoking, 
alcohol consumption, family history of dementia, activities of daily living, instrumental activities 
of daily living, antecedents of chronic diseases, and health status). Participants who reported 
previous vaccination against diphtheria/tetanus (OR = 0.41 [0.27 - 0.62]) and poliomyelitis (OR 
= 0.60 [0.37 - 0.99]) were found to have significantly lower risk of AD while previous receipt of 
influenza vaccine did lower AD risk, but the reduction was not statistically significant (OR = 
0.75 [0.54 - 1.04]).  
 
2. In utero exposure to the 1918 pandemic influenza in Denmark and risk of dementia 
(Cocoros et al., 2018). 
 Cocoros et al. hypothesized that in utero exposure to influenza infection may be linked to 
the development of AD. The investigators of the study first used influenza surveillance data from 
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1915 to 1922 in Denmark to determine the peak months of the 1918 influenza pandemic. Then, 
they designed a cohort study that identified individuals in the Danish National Patient Registry 
(DNPR) and the Psychiatric Central Research Registry (PCRR) who were in utero for at least 
one month of the peak influenza pandemic months. Control group was comprised of individuals 
who were matched to those in the exposure group but were born before or after the peak 
influenza pandemic months.  
 The exposed group contained 106,479 participants, and unexposed group contained 
177,918 participants. Investigators used Poisson regression to calculate incidence rate ratios 
which were stratified by sex and 10-year age groups. In brief, the study did not find a significant 
association between in utero influenza exposure and any dementia diagnosis for all ages: 
incidence rate ratios (IRR) = 1.01 (0.99 – 1.04). Analysis stratified by age (10-year blocks) 
revealed IRR 0.89 (0.82 – 0.96) for 62 to 72- year-old participants, IRR 1.06 (1.02 – 1.10) for 72 
to 82-year-old participants, and IRR 1.01 (0.98 – 1.04) for 82 – 92-year-old participants. 
Analysis by dementia type did not reveal a significant association between in utero influenza 
exposure and dementia diagnosis. 
 
3. Influenza infections and risk of Alzheimer’s disease (Imfeld et al., 2016a). 
 Imfeld et al. designed a case-control study using the Clinical Practice Research Datalink 
(CPRD), which contains medical records of approximately 10 million people in the United 
Kingdom. They identified subjects (cases) who were 65 years or older who were diagnosed with 
AD using the database. For each subject enrolled in the “case” group, the investigators enrolled 
one cognitively unimpaired patient, matched by important confounders (age, sex, calendar time 
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(controls were assigned “diagnosis date” of their corresponding case subjects), general medical 
practice, and the number of years of data available in CPRD).  
 The main exposure measures in the study were the number of influenza infections and the 
timing of the last influenza infection prior to index date, which is the date of first diagnosis or 
first prescription of AD medication. The study also obtained information regarding underlying 
inflammatory conditions that could increase the risk of AD as well as clinical complications after 
influenza infection. In addition, multiple possible confounders were measured in the study 
including age, sex, body mass index (BMI), smoking status, comorbidities, and co-medications.  
The study included large number of subjects (N=19,463 in each arm). Authors found that 
previous influenza infection was not associated with AD with OR 0.94 (0.87 – 1.02) when 
adjusted for BMI and smoking status. Dose-response was not seen with increasing number of 
influenza infection episodes. OR (adjusted) for 1, 2, and >3 prior episodes were 0.98 (0.90 – 
1.07), 0.70 (0.56 – 0.88), and 0.92 (0.63 – 1.34), respectively. In addition, the number of years 
since the last episode of influenza infection did not show statistically significant association with 
AD (OR = 0.69 [0.50 – 0.96] for < 1 year, OR = 0.93 [0.75 – 1.15] for 1-3 years, OR = 0.95 
[0.87 – 1.03] for > 3 years). Association between influenza infections and AD stratified by the 
presence or absence of chronic inflammatory condition also did not reveal statistical significance 
(OR = 0.97 [0.88 – 1.06] for influenza without chronic inflammatory condition, OR = 0.83 [0.72 
– 0.96] for influenza with chronic inflammatory condition). 
 
Discussion 
 The three included studies were heterogeneous in terms of exposures, with one study 
measuring previous influenza vaccine administration and two studies measuring previous 
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influenza virus infection/exposure; however, studies were consistent in finding no association 
between influenza and AD. One study used self-reported vaccination history from the CSHA 
cohort and found a trend towards decreased risk of AD among participants with a previous 
exposure to the influenza vaccine, however, the association was not statistically significant (OR 
= 0.75 [0.54-1.04]). Studies by Cocoros et al. (Cocoros et al., 2018) and Imfeld et al. (Imfeld, 
Toovey, Jick, & Meier, 2016b) also did not show any association between influenza infection 
and risk of developing AD.  
 The three studies examined in this systematic review shared several common limitations. 
First, although the influenza virus has been shown to induce neuroinflammation and 
neurodegeneration that could result in accumulation of amyloid-beta proteins in murine models 
(Jang et al., 2009), it is difficult to confirm this association at the population level using existing 
research or medical record databases. All three studies were limited in their ability to determine 
both the extent of exposure and the timing of exposure to either influenza or the influenza 
vaccine due to unreliable exposure measurements. Verreault et al. study asked participants via a 
questionnaire whether they had ever received the influenza vaccination, but they did not ask 
when the vaccine was administered or how many times influenza vaccine was administered. This 
limitation prevented investigators from assessing the effectiveness of an exposure threshold, if it 
exists, of the influenza vaccination. In other words, it was not possible to determine how many 
influenza vaccine administrations could potentially decrease the risk of AD (or how many 
influenza infections could potentially increase the risk of AD). Similarly, Imfeld et al. could only 
stratify the timing of influenza infection into three categories (<1, 1 – 3, > 3 years) and the 
majority of these categories would have resulted in a short time interval between influenza and 
first diagnosis of dementia. This stratification is most likely not granular enough to determine the 
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critical point that influenza may play a role in the pathogenesis of AD. These limitations are 
perhaps unavoidable when conducting large epidemiological studies of AD which takes many 
years to develop and has an unclear pathogenesis.  
 Likewise, the study by Cocoros et al. examining the relationship between in utero 
influenza exposure and risk of AD used birth dates of participants to determine whether they 
were exposed to influenza virus in utero during 1918 pandemic. The researchers cite a previous 
study that examined mortality rate during the pandemic to determine peak months (Bloom-
Feshbach et al., 2011). However, it is not possible to determine actual exposure to in utero 
influenza exposure from this data, and thus, using peak months as a proxy measure for in utero 
exposure of influenza may introduce exposure classification error. In addition, because control 
participants were in utero during months immediately before or after peak months, it is suspected 
that the difference in in utero influenza exposure between exposed group and control group is not 
pronounced enough to detect a difference in AD risk later in life.  
Finally, the Verreault et al. study used a self-administered questionnaire to ascertain 
exposure status (tetanus/diphtheria, poliomyelitis, and influenza vaccine) and reported an odds 
ratio less than 1.0, albeit not statistically significant. As with any other studies that rely on 
questionnaires, there is a risk of recall bias. Also, it may be the case that participants who 
developed AD later in the study had other underlying risk factors for AD. From the baseline 
characteristics table of the study, it can be seen that participants who developed AD were older, 
predominantly female, and were less educated than controls. It is possible that the difference in 
vaccination rates observed in the study could be attributed to other unmeasured but related 
socioeconomic risk factors that confounded the results. 
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 Finally, using AD diagnosis as an outcome measurement can inherently introduce 
imprecision to the study, especially when extracted from medical records. Both Cocoros et al. 
and Imfeld et al. studies used AD diagnosis codes in the Danish National Patient Registry or 
Clinical Practice Research Datalink, respectively. The study by Mattson et al. (from 2012) found 
that when using neuropathological examination (autopsy) as the gold standard, clinical diagnosis 
of AD had sensitivity of  70.9% to 87.3% and specificity from 44.3% to 70.8% (Mattsson et al., 
2012). Thus, extracting AD diagnosis from medical records can add to this imprecision by 
having numerous physicians using inconsistent guidelines to arrive at the same diagnosis. 
Verreault et al. attempted to mitigate the introduction of this imprecision by conducting their 
own follow-up and diagnosis using consistent guidelines (DSM-IV criteria).  
 
Conclusion 
 This systematic review searched for evidence examining the association between 
influenza vaccine or virus and AD. There is unfortunately not enough literature on this topic to 
conclusively and quantitatively determine the strength of this association. The three studies 
described in this review were conducted in three different developed countries (United Kingdom, 
Denmark, and Canada) using data on a relatively large number of participants. However, due to 
the nature of AD, which takes years (perhaps decades) to develop and the difficulty of obtaining 
sizable and granular data on influenza infection/vaccination, the results of the three studies 
should be interpreted with some reservation as discussed above.  
However, it is worth pursuing future studies to further characterize the association 
between influenza and AD. There are several studies that have established an association 
between influenza virus and neurostructural changes seen in AD in murine models (Jang et al., 
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2009; Maurizi, 2002). Future studies should aim to use databases with an extensive longitudinal 
record of either influenza vaccination administration or influenza infection or both. Using 
databases that contain medical records stretching back decades before the diagnosis of AD will 
be important in establishing a credible association between influenza and AD. Finally, as 
indicated above, future studies must use consistent AD diagnostic criteria to ensure minimization 
of misclassification and granular measures of influenza infection or vaccination to enable 
calculation of “dose-response.” 
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Appendix A: Tables and Figures 
Figure 1: Flow Diagram of Article Inclusion
 
Table 1: Inclusion and Exclusion Criteria 
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Table 2: Boolean Search Terms 
Database Search Terms 
PUBMED Search (((((((((vaccines OR vaccine* OR vaccinat* 
OR toxoid* OR immunization) OR (influenza* OR 
influenzavirus OR flu[MeSH Terms]))) AND 
((alzheimer's disease OR alzheimer* OR dementia 
OR "cognitive impairment, mild" OR "mild 
cognitive impairment" OR "cognitive impairment 
with no dementia" OR "senile dementia"[MeSH 
Terms])))) AND ("1984"[Date - Publication] : 
"3000"[Date - Publication])) AND 
English[Language]) AND Humans[Mesh])) AND 
(“cohort” OR “case-control” OR “randomized” OR 
“prospective” OR “retrospective” OR “clinical trial” 
OR “cross-section” OR “cross-sectional” OR 
“crosssection” OR “crosssectional”) NOT 
(“alzheimer’s vaccine” OR “alzheimer’s disease 
vaccine” OR “tau vaccine” OR “pediatric” OR 
immunotherapy OR “HIV”[MeSH Terms]) Sort by: 
Best Match Filters: Humans 
ESBO (SU (vaccines OR vaccine* OR vaccinat* OR 
toxoid* OR immunization) OR (influenza* OR 
influenzavirus OR flu)) AND (SU ((alzheimer's 
AND disease) OR alzheimer* OR dementia OR 
"cognitive impairment, mild" OR "mild cognitive 
impairment" OR "cognitive impairment with no 
dementia" OR "senile dementia")) NOT (TX (tau 
AND vaccine)) NOT (TX pediatric) NOT (TX 
immunotherapy) NOT (TX hiv/aids) NOT (TX 
mice) NOT (TX (alzheimers AND disease AND 
vaccine)) NOT (TX ("in" AND brief)) 
PsycINFO 
 
( ((vaccines OR vaccine* OR vaccinat* OR toxoid*) 
OR (influenza* OR influenzavirus OR flu)) ) AND 
( (alzheimer's disease OR alzheimer* OR dementia 
OR "cognitive impairment, mild" OR "mild 
cognitive impairment" OR "cognitive impairment 
with no dementia" OR "senile dementia") ) AND 
( (“cohort” OR “case-control” OR “randomized” OR 
“prospective” OR “retrospective” OR “clinical trial” 
OR “cross-section” OR “cross-sectional” OR 
“crosssection” OR “crosssectional") ) NOT 
( (“alzheimer’s vaccine” OR “alzheimer’s disease 
vaccine” OR “tau vaccine” OR pediatric[MeSH 
Terms] OR “pediatric” OR immunotherapy OR 
“HIV”) ) 
EMBASE 
 
('vaccine':ti,ab,kw OR 'live vaccine':ti,ab,kw OR 
'immunization':ti,ab,kw OR 'toxoid':ti,ab,kw) AND 
('alzheimer disease':ti,ab,kw OR 'dementia':ti,ab,kw 
OR 'mild cognitive impairment':ti,ab,kw OR 'senile 
dementia':ti,ab,kw) AND human NOT animal NOT 
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pediatrics AND [1984-2018]/py AND [english]/lim 
AND ([middle aged]/lim OR [aged]/lim) 
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Appendix C: Quality Assessment Tables 
 
Study Study Information 
 
Participants Risk Factor and 
Outcome 
Assessment 
Results Comments/Quality Scoring 
Cocoros, 
2018 
 
 
 
 
 
 
Geographical 
location: Denmark 
(Copenhagen, “other 
towns,” and “rural 
districts”). 
 
Setting:  
Mixed: Inpatient and 
Outpatient. 
 
Study design:  
Retrospective cohort. 
 
Number of 
participants enrolled:    
Unexposed: 106,479 
Exposed: 177,918 
 
Duration of follow up:   
Maximum of 30 years 
(age 62 – 92). Median 
follow-up for exposed 
and unexposed was 
18.2 years 
(interquartile range 
11.0-24.8)  
 
Time from risk factor 
assessment to final 
cognitive 
assessment:     
Minimum of 62 years 
(in utero exposure date 
of birth and monitoring 
for dementia from age 
62-92). 
Age:   
Range: 62-92 yrs old 
 
Sex: [n (%)] 
Female: 52% 
Male: 48% 
 
Race/ethnicity: [n (%)]  
NR 
  
Baseline cognitive 
status: 
Non-demented 
 
Inclusion criteria:   
1) Persons born in 
Denmark from 
December 1915 to 
December 1921 who 
are present in 
Danish National 
Patient Registry and 
Psychiatric Central 
Research Registry. 
 
Exclusion criteria:   
1) Dementia diagnosis 
code of interest in 
the Danish National 
Patient Registry and 
Psychiatric Central 
Research Registry 
prior to their index 
date (year they 
turned 62). 
2) Mild cognitive 
impairment or 
amnestic syndrome 
documented prior to 
index date. 
Risk factor/exposure 
1:  
In utero exposure to 
influenza pandemic 
(birth dates from 
November 2018 
through October 1920). 
 
Method of assessing 
risk factor/exposure 
1: In utero >1 month 
during peak months of 
influenza-like illness 
from 1915- 1922. 
 
Covariates/potential 
confounders 
adjusted for in 
analyses:  
Sex 
 
Method(s) of 
assessing dementia: 
Diagnosis of dementia 
(of any type) based on 
inpatient or outpatient 
hospital- based contact 
documented in the 
Danish National 
Patient Registry or the 
Psychiatric Central 
Research Registry 
 
Informant interview?: 
No 
1) Follow-up rate: 
Cohort defined by those who were 
born in specified years and survived 
to the age of 62.  
Percent followed 11-20 years: 78%, 
78% (unexposed, exposed, 
respectively).  
Percent followed 21-30 years: 43%, 
43% (unexposed, exposed, 
respectively). 
 
2) Important baseline differences: 
No significant baseline differences 
between exposed and unexposed 
groups. 
 
3) Outcome of interest #1  
No difference in unadjusted rates of 
dementia among exposed (11.9%) 
and unexposed (11.7%) individuals. 
 
No evidence that sex was a modifier 
of the relationship as female IRR 
1.02 (95% CI, 0.99-1.05) and male 
strata IRR 1.01 (CI 0.97-1.05) 
yielded similar results for the 
combined age groups for dementia.  
   
Outcome of interest #2 
No difference between unexposed 
and exposed in unadjusted rates of 
Alzheimer’s disease (2.1% vs. 1.9%), 
vascular dementia (0.85% vs. 
0.86%), other forms of dementia 
(5.4% vs. 5.6%). 
 
Comments: 
Large retrospective cohort study 
using national databases in 
Denmark. Exposure measurement 
(in utero exposure to influenza 
approximated by date of birth) may 
not be a valid measure. The study 
could have examined more possible 
confounders (in addition to age and 
sex).  
 
Quality assessment:   
For observational studies:  
1) Unbiased selection of the 
cohort?: Yes 
2) Selection minimizes baseline 
differences in prognostic 
factors?: Partially 
3) Sample size calculated/5% 
difference?: Yes 
4) Adequate description of the 
cohort?: No 
5) Validated method for 
ascertaining exposure?: No 
6) Validated method for 
ascertaining clinical outcomes? 
Partially 
7) Outcome assessment blind to 
exposure?: Yes 
8) Adequate follow-up period?: Yes 
9) Completeness of follow-up?: 
Partially 
10) Analysis controls for 
confounding?:   
11) Analytic methods appropriate?: 
Yes 
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Study Study Information 
 
Participants Risk Factor and 
Outcome 
Assessment 
Results Comments/Quality Scoring 
     
Verreault 
2001 
 
 
 
 
 
 
Geographical 
location: Canada  
 
Setting: 
Community 
 
Study design: 
Prospective cohort  
 
Number of 
participants enrolled:    
4392 eligible 
participants enrolled at 
baseline. 
3865 participants data 
analyzed (527 became 
ineligible due to being 
diagnosed with 
cognitive impairment or 
dementia other than 
AD). 
 
Duration of follow up:    
5 years 
 
Time from risk factor 
assessment to 
diagnosis of AD: 
Unknown; Diagnosis of 
AD was made at 
follow-up 5 years after 
enrollment.  
Vaccination information 
was gathered using 
questionnaire and 
timing of vaccine 
receipt was not 
available. 
Age:   
AD group: 81 yrs old 
Control: 72 yrs old 
 
Sex: [n (%)] 
Overall: 
    Female: 2330 (60.3) 
    Male: 1535 (39.7) 
AD group: 
    Female: 123 (67.2) 
    Male: 60 (32.8) 
Control: 
    Female: 2207 (59.9) 
    Male: 1475 (40.0) 
 
Race/ethnicity: [n (%)] 
NR 
 
Baseline cognitive 
status:  
Cognitively unimpaired 
 
Inclusion criteria:   
1) Participants are 
part of Canadian 
Study of Health 
and Aging. 
2) Age 65 or older. 
3) Cognitively 
unimpaired at 
baseline. 
 
Exclusion criteria:   
1) Cognitively 
impaired at 
baseline. 
2) Age younger than 
65. 
Risk factor/exposure 
1:  
Past exposure to 
vaccines (tetanus, 
diphtheria, 
poliomyelitis, influenza) 
 
Method of assessing 
risk factor/exposure 
1:  
Self-administered risk 
factor questionnaire 
 
Covariates/potential 
confounders 
adjusted for in 
analyses:  
Age 
Sex 
Years of education 
Current smoking status 
Regular alcohol 
consumption 
Family history of 
dementia 
ADL and IADL scores 
Number of chronic 
diseases 
Perceived good health 
 
Method(s) of 
assessing cognitive 
status:  
NINCDS-ADRDA 
DSM 
 
Informant interview?: 
No 
 
 
 
1) Follow-up rate: 
3865 participants who were either 
cognitively normal or newly 
diagnosed with Alzheimer’s Disease 
at CSHA-2 
4392 = (88.0%) 
 
2) Important baseline differences: 
AD group compared to control group: 
    Older 
    More females 
    Fewer years of education 
 
3) Outcome of interest #1 
Alzheimer’s Disease:  
diagnosed independently by the   
physician and the neurophysiologist 
using DSM-III criteria and the 
NINCDS-ADRDA. 
Comments: 
The only large prospective cohort 
study that examined the relationship 
between vaccination and the risk of 
developing AD. The use of self-
reported questionnaires could have 
led to underreporting of vaccine rates 
and recall bias, and 5-year follow-up 
period may not be adequate for 
detecting development of AD.  
 
Quality assessment:   
For observational studies:  
12) Unbiased selection of the 
cohort?:  Yes 
13) Selection minimizes baseline 
differences in prognostic 
factors?: Partially 
14) Sample size calculated/5% 
difference?: Yes  
15) Adequate description of the 
cohort?: Partially 
16) Validated method for 
ascertaining exposure?: Partially 
17) Validated method for 
ascertaining clinical outcomes?: 
Yes 
18) Outcome assessment blind to 
exposure?: Can’t tell 
19) Adequate follow-up period?: No. 
20) Completeness of follow-up?: Yes 
21) Analysis controls for 
confounding?: Yes 
22) Analytic methods appropriate?: 
Yes 
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Study Study Information 
 
Participants Risk Factor and 
Outcome 
Assessment 
Results Comments/Quality Scoring 
      
Imfeld, 
2015 
 
 
 
 
 
 
Geographical 
location: United 
Kingdom 
 
Setting: 
Community (Clinical 
Practice Research 
Datalink) 
 
Study design:  
Nested case-control 
study 
 
Number of 
participants enrolled:    
19,463 cases 
19,463 controls 
 
 
Duration of follow up:    
Unspecified; 
The study divided 
number of years since 
the last episode into 4 
categories (0, <1, 1-3, 
>3). 
 
Time from risk factor 
assessment to final 
cognitive 
assessment:     
NR 
 
 
Age:   
Estimated mean: 81.5 yrs 
old (from Table 1) 
 
Sex: [n (%)] 
Female: 26,714 (68.6) 
Male: 12,212 (31.4) 
 
Race/ethnicity: 
NR 
 
Baseline cognitive 
status:   
Non-demented 
 
Inclusion criteria:   
1) Age 65 or older. 
2) First time diagnosis 
of AD or any 
unspecified dementia 
recorded between 
January 1998 and 
July 2013. 
3) First-time 
prescription for an 
acetylcholinesterase 
inhibitor or NMDA-
receptor antagonist. 
 
Exclusion criteria:   
1) Less than 3 years of 
active history in the 
database prior to the 
index date. 
2) Diagnosis of 
HIV/AIDS, 
alcoholism, drug 
abuse, MS, motor 
neuron disease, or 
Down’s syndrome. 
Risk factor/exposure 
1:  
Previous influenza 
diagnosis. 
 
Risk factor/exposure 
2:  
Number of previous 
influenza infections. 
 
Risk factor/exposure 
3:  
Timing of the last 
influenza infection prior 
to the index date. 
 
Method of assessing 
risk factors/exposures: 
Medical record: Read-
codes in CPRD. 
 
Covariates/potential 
confounders adjusted 
for in analyses:  
Age 
Sex 
BMI 
Smoking status 
Comorbidities 
Co-medications 
 
Method(s) of 
assessing cognitive 
status: 
Read-codes in CPRD. 
No direct cognitive 
measurement. 
 
Informant interview?: 
No 
 
1) Follow-up rate: 
NR; nested case-control study 
 
2) Important baseline differences: 
Controls had significantly more 
obese patients and current smokers. 
Comorbidities: 
Significant differences in arterial 
hypertension, DM, atrial fibrillation, 
heart failure, asthma, COPD, 
depression. 
All above comorbidities were higher 
in controls except depression. 
 
3) Outcome of interest #1 
Cases comprised of participants with 
first-time diagnosis of AD, any 
unspecified dementia, and first-time 
prescription for an 
acetylcholinesterase inhibitor or 
NMDA-receptor antagonist. 
 
 
 
 
 
 
 
 
 
Comments: 
Extensive nested case-control study 
with large number of participants 
using well-validated research 
database (CPRD). Selection bias 
was minimal due to the 
comprehensive nature of the 
database used, and the study also 
accounted for multiple possible 
confounders.  
 
Quality assessment:   
For observational studies:  
23) Unbiased selection of the 
cohort?:  Yes 
24) Selection minimizes baseline 
differences in prognostic 
factors?:  Yes 
25) Sample size calculated/5% 
difference?: Yes 
26) Adequate description of the 
cohort?:  Yes 
27) Validated method for 
ascertaining exposure?: Yes 
28) Validated method for 
ascertaining clinical outcomes?: 
Yes 
29) Outcome assessment blind to 
exposure?: Yes 
30) Adequate follow-up period?: 
Can’t tell 
31) Completeness of follow-up?: Yes 
32) Analysis controls for 
confounding?: Yes 
33) Analytic methods appropriate?: 
Yes 
 
